Moderna, Inc. (MRNA) Stock
Healthcare · Biotechnology · Member of S&P 500, NASDAQ 100
Moderna, Inc. (MRNA) closed at USD 226.30 on 2026-10-14, a change of +792.7 % over the past year, with a market capitalization of USD 94.42B.
Moderna, Inc. recent closing prices
| Date | Close (USD) |
|---|---|
| 2026-10-14 | 226.30 |
| 2026-10-13 | 216.25 |
| 2026-10-12 | 213.74 |
| 2026-10-09 | 225.00 |
| 2026-10-08 | 197.00 |
| 2026-10-07 | 196.48 |
| 2026-10-06 | 187.46 |
The most recent trading day is not shown. For full charts and indicators use the analysis page.
Moderna, Inc. key figures
- Previous close
- USD 226.30 (2026-10-14)
- 1-year change
- +792.7 %
- Market cap
- USD 94.42B
- Enterprise value
- USD 90.57B
- P/E ratio (trailing)
- -27.09
- P/E ratio (forward)
- -53.29
- EPS (trailing)
- -8.73
- EPS (forward)
- -4.44
- PEG ratio
- n/a
- Price to book
- 13.96
- Revenue growth
- 2.1 %
- Earnings growth
- n/a
- Dividend per share (trailing)
- 0.00
- Short ratio
- 2.00
- Employees
- 4,700
- Analyst consensus (third-party)
- hold
Source: Yahoo Finance via yfinance. Data may be delayed, incomplete or incorrect.
About Moderna, Inc.
Moderna, Inc., a biotechnology company, provides messenger RNA medicines in the United States, Europe, and internationally. The company's respiratory vaccines include spikevax, mNEXSPIKE, mRESVIA, COVID, RSV, seasonal influenza, combination, and pandemic influenza vaccine; latent vaccines comprise cytomegalovirus, epstein-barr virus, and human immunodeficiency virus vaccines; enteric viruses include norovirus; public health vaccines consist of Zika, Nipah, and Mpox vaccines; and bacterial diseases vaccines, such as lyme vaccines. It also provides oncology therapeutics, such as intismeran autogene, cancer antigen therapy, t-cell engager, and cell therapy enhancer; and rare disease products, including propionic and methylmalonic acidemia, and cystic fibrosis. It has strategic alliances and collaborations with Merck & Co., Inc; Vertex Pharmaceuticals Incorporated; Vertex Pharmaceuticals (Europe) Limited; immatics N.V.; Defense Advanced Research Projects Agency; Biomedical Advanced Research and Development Authority; Institute for Life Changing Medicines; The Bill & Melinda Gates Foundation; and OpenAI. The company was formerly known as Moderna Therapeutics, Inc. and changed its name to Moderna, Inc. in August 2018. Moderna, Inc. was founded in 2010 and is headquartered in Cambridge, Massachusetts.
Technical indicators and comparison
Show RSI, MACD, EMA, CCI and ADX for Moderna, Inc. and compare it with other stocks.
Analyze MRNAAll S&P 500 stocksStock-scoring.com provides this page for information only. It is not investment advice or a recommendation to buy or sell Moderna, Inc. shares.